Cargando…

Differential SPARC mRNA expression in Barrett's oesophagus

Barrett's oesophagus (BE) is the precursor lesion to adenocarcinoma of the oesophagus. Understanding of the molecular alterations in this multistage process may contribute to improved diagnosis and treatment. Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein that m...

Descripción completa

Detalles Bibliográficos
Autores principales: Brabender, J, Lord, R V, Metzger, R, Park, J, Salonga, D, Danenberg, K D, Danenberg, P V, Hölscher, A H, Schneider, P M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394336/
https://www.ncbi.nlm.nih.gov/pubmed/14562024
http://dx.doi.org/10.1038/sj.bjc.6601324
_version_ 1782155391936757760
author Brabender, J
Lord, R V
Metzger, R
Park, J
Salonga, D
Danenberg, K D
Danenberg, P V
Hölscher, A H
Schneider, P M
author_facet Brabender, J
Lord, R V
Metzger, R
Park, J
Salonga, D
Danenberg, K D
Danenberg, P V
Hölscher, A H
Schneider, P M
author_sort Brabender, J
collection PubMed
description Barrett's oesophagus (BE) is the precursor lesion to adenocarcinoma of the oesophagus. Understanding of the molecular alterations in this multistage process may contribute to improved diagnosis and treatment. Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein that modulates cell adhesion and growth. Alterations in SPARC expression have been observed in a variety of solid tumours. The aim of this study was to assess the prevalence and timing of SPARC mRNA expression in Barrett's multistage disease and to investigate the impact of SPARC alterations on the development and progression of this disease. SPARC mRNA expression was measured using a quantitative real-time RT–PCR method in 108 specimens from 19 patients with BE without carcinoma, 20 patients with Barrett's-associated adenocarcinoma (EA), and a control group (CG) of 10 patients without evidence of gastro-oesophageal reflux disease. The median SPARC mRNA expression was significantly upregulated in BE tissues compared to paired normal oesophagus (NE) tissues for the BE group (P=0.004) and for the EA group (P<0.001). The SPARC mRNA expression was significantly higher in adenocarcinoma of the oesophagus compared to matching NE tissue and compared to Barrett's tissues in the EA group (P<0.001). Furthermore, SPARC expression values were significantly different between metaplastic and dysplastic Barrett's tissues (P=0.014). In histologically normal squamous oesophagus tissues obtained from carcinoma patients (EA group), the SPARC mRNA expression was significantly higher compared to NE mucosa from the BE group and the CG group (P=0.03). These findings suggest that the upregulation of SPARC mRNA expression is an early event in the development and progression of BE and EA, and that high SPARC expression may be a clinically useful biomarker for the detection of occult adenocarcinoma, and that a widespread ‘field effect’ is present in the NE of patients with oesophageal adenocarcinoma.
format Text
id pubmed-2394336
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23943362009-09-10 Differential SPARC mRNA expression in Barrett's oesophagus Brabender, J Lord, R V Metzger, R Park, J Salonga, D Danenberg, K D Danenberg, P V Hölscher, A H Schneider, P M Br J Cancer Molecular and Cellular Pathology Barrett's oesophagus (BE) is the precursor lesion to adenocarcinoma of the oesophagus. Understanding of the molecular alterations in this multistage process may contribute to improved diagnosis and treatment. Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein that modulates cell adhesion and growth. Alterations in SPARC expression have been observed in a variety of solid tumours. The aim of this study was to assess the prevalence and timing of SPARC mRNA expression in Barrett's multistage disease and to investigate the impact of SPARC alterations on the development and progression of this disease. SPARC mRNA expression was measured using a quantitative real-time RT–PCR method in 108 specimens from 19 patients with BE without carcinoma, 20 patients with Barrett's-associated adenocarcinoma (EA), and a control group (CG) of 10 patients without evidence of gastro-oesophageal reflux disease. The median SPARC mRNA expression was significantly upregulated in BE tissues compared to paired normal oesophagus (NE) tissues for the BE group (P=0.004) and for the EA group (P<0.001). The SPARC mRNA expression was significantly higher in adenocarcinoma of the oesophagus compared to matching NE tissue and compared to Barrett's tissues in the EA group (P<0.001). Furthermore, SPARC expression values were significantly different between metaplastic and dysplastic Barrett's tissues (P=0.014). In histologically normal squamous oesophagus tissues obtained from carcinoma patients (EA group), the SPARC mRNA expression was significantly higher compared to NE mucosa from the BE group and the CG group (P=0.03). These findings suggest that the upregulation of SPARC mRNA expression is an early event in the development and progression of BE and EA, and that high SPARC expression may be a clinically useful biomarker for the detection of occult adenocarcinoma, and that a widespread ‘field effect’ is present in the NE of patients with oesophageal adenocarcinoma. Nature Publishing Group 2003-10-20 2003-10-14 /pmc/articles/PMC2394336/ /pubmed/14562024 http://dx.doi.org/10.1038/sj.bjc.6601324 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular and Cellular Pathology
Brabender, J
Lord, R V
Metzger, R
Park, J
Salonga, D
Danenberg, K D
Danenberg, P V
Hölscher, A H
Schneider, P M
Differential SPARC mRNA expression in Barrett's oesophagus
title Differential SPARC mRNA expression in Barrett's oesophagus
title_full Differential SPARC mRNA expression in Barrett's oesophagus
title_fullStr Differential SPARC mRNA expression in Barrett's oesophagus
title_full_unstemmed Differential SPARC mRNA expression in Barrett's oesophagus
title_short Differential SPARC mRNA expression in Barrett's oesophagus
title_sort differential sparc mrna expression in barrett's oesophagus
topic Molecular and Cellular Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394336/
https://www.ncbi.nlm.nih.gov/pubmed/14562024
http://dx.doi.org/10.1038/sj.bjc.6601324
work_keys_str_mv AT brabenderj differentialsparcmrnaexpressioninbarrettsoesophagus
AT lordrv differentialsparcmrnaexpressioninbarrettsoesophagus
AT metzgerr differentialsparcmrnaexpressioninbarrettsoesophagus
AT parkj differentialsparcmrnaexpressioninbarrettsoesophagus
AT salongad differentialsparcmrnaexpressioninbarrettsoesophagus
AT danenbergkd differentialsparcmrnaexpressioninbarrettsoesophagus
AT danenbergpv differentialsparcmrnaexpressioninbarrettsoesophagus
AT holscherah differentialsparcmrnaexpressioninbarrettsoesophagus
AT schneiderpm differentialsparcmrnaexpressioninbarrettsoesophagus